Dr. René Bressinck CV
Explore the History of this Central Arkansas Board-Certified Dermatologist
Business Address
| Private Practice, Dermatology Dermatology Group of Arkansas Medical Towers 1, Suite 690 9601 Baptist Health Drive Little Rock, Arkansas 72205 |
1978-present |
| Telephone: 501-227-8422 FAX: 501-537-1079 |
|
| Associate Professor of Dermatology University of Arkansas for Medical Sciences |
Education
| Bachelor of Science, Biology University of Arkansas, Little Rock Little Rock, Arkansas | 1967 |
| Doctor of Medicine University of Arkansas Medical Sciences Little Rock, Arkansas |
1970 |
| Internship St. John’s Hospital Tulsa, Oklahoma |
1971 |
| Internal Medicine Residency Tulsa Internal Medicine Foundation |
1972 |
| Dermatology Residency University of Arkansas Medical Sciences |
1973-1975 |
| Chief of Dermatology March Air Force Base | 1975-1978 |
Licensure
| Arkansas | 1970 |
Certifications and Awards
| Board Certified Dermatology AMA, Physician Recognition Award |
1976 |
Community Service
Symphony Board
Arkansas Repertory Theater Board
Assistant Scout Master, BSA
Professional Affiliations
Fellow, American Academy of Dermatology Pulaski County Medical Society
Arkansas Dermatology Society Pacific Dermatology Association Dermatology Foundation
American Society of Laser Medicine and Surgery American Society Dermatology Surgery Honorary Fellow, Skin Cancer Foundation, 1981
Member, Medical Services Review Committee of Arkansas Medical Society, 1982-1983 Past President, Arkansas Dermatology Society, 1983-1984
Member, Public Education Committee, American Cancer Society, 1993.
Meet Your Doctors
Meet Your Doctors
RESEARCH EXPERIENCE
| “A Randomized, Double-Blind, Placebo Controlled Study of the Safety and Efficacy of an Antifungal Topical Patch in the Treatment of Distal Subungual Onychomycosis of the Great Toenail.” | 2011 |
| “A randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Multicenter Study Assessing the Effects Hormone Replacement Therapy in the Improvement of Moderate ‘to Severe Age-Related Skin Changes in Post Menopausal Women.” | 2011 |
| “A Phase lllb; Randomized, Double-blind, Parallel-Group, Placebo-Controlled, Multi-Center Study to Evaluate the Efficacy and Safety of a Subcutaneously Administered Medication in Adults with Moderate to Severe Plaque Psoriasis.” | 2002 |
| “A:Phase Ill Multicenter Study of The Safety and Efficacy of an Injectable TNF in Psoriasis.” | 2002 |
| “A Randomized Third Party Blind, Multicenter Trial Comparing the Efficacy and Safety of Two Different Antifungals given once daily to Pediatric Patients with Tinea Capitis.” | 2002 |
| “A Multicenter, Randomized, Double-Blind, Double-Dummy, Parallel Group Study To Assess The Safety And Tolerability Of A New Oral Formulation Of Antifungal Medication In Patients With Onychomycosis Of The Toenails.” | 2002 |
| “A Phase 111B, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Multi-Center Study To Evaluate The Safety Of A Subcutaneously Administered Medication In Adults With Moderate To Severe, Plaque Psoriasis Who Are Candidates For Systemic Therapy.” | 2002 |
| “A Randomized, Double-Blind, Placebo-Controlled, Phase II Dose Ranging Study of an Oral Slow Release Formulation of an Antibiotic as Primary Therapy for Acne Vulgaris in Participants 12-30 Years of Age.” | |
| “A Randomized, Third Party Blind, Multicenter Trial Comparing the Efficacy and safety of An Anti-fungal Medication Given For 3 Weeks Versus an Antifungal Given for 6 Weeks Versus An Antifungal Given for 6 Weeks Once Daily to Pediatric Patients with Tinea Capitis.” | |
| “An Open Label, Multicenter Trial of an Antifungal for Six Weeks Given Once Daily to Pediatric Patients with Tinea Capitis.” | |
| “A Double Blind, Placebo Controlled, Randomized Parallel Group Clinical Trial of a subcutaneously administered Human Monoclonal Antibody in Patients with Moderate to Severe Chronic Plaque Psoriasis Vulgaris.” | 2002 |
| “An Open Label, Multi-Center Study to evaluate the safety Of A subcutaneously Administered Monoclonal Antibody in Adults with Plaque Psoriasis Previously Enrolled in Study ACD2600g.” | 2003 |
| “A Phase III Multicenter Study to Assess the Efficacy and Safety of Etanercept 50 mg Twice Weekly in Psoriasis” | |
| “A Multi-Center Phase 3, Randomized, Double-Blind, 4-Arm Clinical Trial to Compare the Safety and Efficacy of a Gel vs. another Gel vs. another Gel vs Gel Vehicle in the Treatment of Acne Vulgaris” | |
| “A Multi-Center Phase 3, Investigator B!ind Clinical Trial to assess the safety and Efficacy of a Gel, 1% as Compared to Gel Vehicle and a Cream, 1% in the Treatment of Rosacea.” | 2003 |
| “Vehicle Controlled Double-Blind Study to Assess the Safety and Efficacy of A Topical Cream Applied Once Daily 3 Days per Week in I or 2 Courses of Treatment of Actinic Keratoses on the Head.” | 2003 |
| “A Phase Ill Multicenter Study to Assess the Efficacy and Safety of Etanercept 50 mg Twice Weekly in Psoriasis” | |
| “A Follow-up Study to Evaluate Sustained Actinic Keratosis Clearance Rates One Year or More after Completion of the 1444-IMIQ< 1445-IMIQ, 1446-IMIQ, and 1447 IMI! Studies.” | 2003 |
| “A Phase II Study of Two Dosing Schedules of an Anti-TNF subcutaneous injection in Subjects with Moderate to Severe Chronic Plaque Psoriasis.” | 2003 |
| “An Open Label, Long-Term Extension Study to Assess the Safety of an Ant1-TNF subcutaneously injected drug in the Treatment of Psoriasis in Adult Subjects” | 2003 |
| “A Double-Blind Placebo Controlled Study of the Recurrence and Re-treatment of Distal Subungual Onychomycosis of the Toenails.” | 2004 |
| “A Phase II Extension Study of Two Dosing Schedules of an Anti-TNF in Sut>jects with moderate to Severe Chronic Plaque Psoriasis.” | 2003 |
| “A Multi-Center, Open Label, Long-Tenn Safety Trial of a Topical Gel in the Treatment of Acne Vulgaris” | |
| “Phase III Vehicle-controlled, Double-blind, Study to Assess the Safety and ‘.Efficacy of a topical cream for the Treatment of Molluscum Contagiosum in Pediatric Patients” | |
| “Phase II, multicenter, Double-blind, Randomized, Dose-ranging Evaluation of the Efficacy of Topical Gel Following Repeated Topical Application in Subjects with Acne Vulgaris. | |
| “A randomized, Investigator Blinded, Active-controlled, parallel group study to compare the efficacy and safety of 6-week treatment with a new pediatric formulation versus 6-week treatment with a pediatric suspension in children with Tinea Capitis” | |
| “A Multi Center Open Label Study to Observe the Effect of an anti-TNF monoclonal antibody on Joint and Skin Disease in Subjects with Psoriatic Arthritis” | |
| “A phase II, Randomized, Double-Blind, Placebo Controlled Study of a Humanized Monoclonal Antibody to Integrin Alpha V Beta, Administered by Subcutaneous Injection to Adults with Plaque Psoriasis” | |
| “Randomized, Double-Blind, Placebo-Controlled Phase III Study of an Extended-Release Formulation of an antibiotic for the Treatment of the Inflammatory Lesions of Acne Vulgaris” | |
| “Randomized, Double-Blind, placebo-Controlled Phase III Study of an Extended-Release Formulation of an antibiotic for the Treatment of the Inflammatory Lesions of Acne Vulgaris” | |
| “An open-Label Safety Study of a New Formulation of an antibiotic for the Treatment of Moderate to Severe Acne” | |
| “A Phase 3, Multicenter, Randomized, Double Blind, Vehicle Controlled Study of the Safety and Efficacy of a Foam, in the Treatment of Adolescent and Pediatric Subjects with Mild to Moderate Atopic Dermatitis.” | |
| “A Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Determine the Effects of Modified Release Capsules Administered Once Daily for the Treatment of Rosacea.” | |
| “A multi-center randomized, double blind, placebo controlled phase III study of a subcutaneously administered biologic in the treatment and re-treatment of subjects with moderate to severe plaque psoriasis.” | |
| “Placebo-controlled Multicenter Study with a biologic to Determine Safety and Efficacy in Pediatric Subjects with Plaque Psoriasis (PEDS)” | |
| “A Phase 3, multi-Center Study of the Efficacy and Safety ofLong-Te1m Biologic Treatment in Subjects with Moderate to Severe Chronic Plaque Psoriasis. | |
| “A randomized, investigator blinded, active-controlled, parallel group study to compare the efficacy and safety of 6- week treatment with a new pediatric formula versus 6-week treatment with an approved pediatric suspension in children with Tinea Capitis” | |
| “A Follow-up Study to Evaluate Actinic Keratosis Recunence Rate One Year after Completion of the 1473-IMIQ Study (IND #49,480).” | |
| “A Randomized, Double-Blind, Placebo-Controlled, Safety and Tolerability Study of a biologic in Subjects with Chronic Plaque Psoriasis Requiring Systemic Therapy.” | |
| “An Open-label Extension Study to Evaluate the Safety of Etanercept in Pediatric Subjects with Plaque Psoriasis.” | |
| “A Randomized, evaluator blinded, vehicle-controlled multi-center study of the safety and efficacy of 4% Trade name Fluorouracil) cream versus its vehicle cream versus Effudex cream in the Treatment of Actinic Keratosis” | |
| “A Phase II, Multi-Center, Randomized, Evaluator-Blind, Vehicle Controlled, 6-Ann, Parallel Group Comparison Study Comparing the Efficacy and Safety of Clinaben (1/2.5), Clindamycin (1%), and Benzoyl Peroxide (2.5%) Gels in the Treatment of Acne Vulgaris.” | |
| “Reptiva Epidemiologic Study of psoriasis Outcomes and Safety Events (RESPONSE) in Patients with Chronic Moderate to severe Plaque Psoriasis” | |
| “Phase 2/3 Study: A Multicenter OpenLabel Continuation Study in Moderate to Sever Plaque Psoriasis Subjects who completed a preceding Psoriasis Clinical Study with Adalimumab” | |
| “A Randomized, Double Blind, Placebo Controlled, Parallel Group Study of the Safety and Efficacy of 1% and 2% Nanocrystalline Sliver Cream (NPI 32101) Applied Twice Daily in Pediatric and Adolescent Subjects with Mild to Moderate Atopic Dermatitis” | |
| “An open-Label, multi-center, uncontrolled, single-group assignment, long-term safety of 4% Trade name (Fluorouracil) cream in subjects with Actinic Keratosis (who participated in the Phase III studies)” | |
| “Observational Post-Marketing Safety Surveillance Registry of Enbrel (entanercept) for the Treatment of Psoriasis” | |
| “A multi-center, randomized, double-blind, parallel-group study to demonstrate the efficacy and safety of adapalene/benzoyl peroxide topical gel compared with adapalene topical gel, 0.1%; benzoyl peroxide topical gel ve_hicle in subjects with acne vulgaris” | |
| “An open-label extension study to evaluate the safety of entercept in pediatric subjects with plaque psoriasis PEDS” | |
| “Pharmacokinetics and Pharmacodynamics of calcitriol following twice daily application of calcitriol 3ug/g ointment under condition of maximal use in adolescents with plaque psoriasis”. | |
| “A phase 3, multicenter, randomized, double-blind, placebo controlled trial evaluating the efficacy and safety of CNTO 1275 in the treatment of subjects with moderate to severe plaque-type psoriasis” | |
| “Raptiva Epidemiologic study of psoriasis outcomes and safety events (RESPONSE) in patients with chronic moderate to severe plaque psoriasis” | |
| “A randomized, double-blind, parallel-group, 4-arm, 12-week study to evaluate the safety and efficacy of topical applied CTA0 18 vs. vehicle for the treatment of adult subjects with chronic plaque psoriasis” | |
| “A multicenter, randomized, double-blind, vehicle-controlled, dose-ranging study to evaluate the safety and efficacy of 0.005%, 0.01% and 0.015% PEP005 Topical Gel when used to treat actinic keratosis on the head, face, or scalp.” | |
| “A phase 4 randomized, double-blind, placebo controlled study to evaluate the safety and efficacy of 1.0 mg/kg Efalizumab in adult patients with moderate to severe plaque psoriasis with involvement of the scalp.” | |
| “A phase 2B multi-center, double-blinded, randomized, dose-ranging clinical trial to evaluate IDP-107 in the treatment of moderate to severe acne vulgaris with nodular involvement.” | |
| “An open-label study of Adalimumab in subjects who have a sub-optimal response to systemic therapy or phototherapy.” (in the treatment of chronic-plaque psoriasis)” | |
| “A phase 3, multi-center, randomized, double-blind, placebo-controlled study comparing the efficacy and safety of- —–to and placebo in subjects with moderate to severe chronic plaque psoriasis.” |
|
| “A phase 3, multi-center, open-label continuation study in moderate to severe chronic plaque psoriasis subjects who completed a preceding psoriasis study with ABT-874”. | |
| “A phase 3, multi-center, randomized, double-blind, placebo-controlled study comparing the safety and efficacy of two dosing regimens of ABT-874 to placebo in subjects with moderate to severe chronic plaque psoriasis.” | |
| “A phase 4, multi-center, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of a 16-week course of subcutaneous Humira 40mg eow compared with placebo in adults with moderate to severe chronic plaque psoriasis involving hands and/or feet and to examine the sustainability of that response for an additional 12 weeks of an open-label treatment.” | |
| “A phase 2B, multi-center, randomized, double-blind, parallel-group, placebo-controlled trial evaluating the efficacy and safely of dose regimens with oral CP-690, 550 in the treatment of subjects with moderate to severe chronic plaque psoriasis.” | |
| “S_CHERING STUDY C86-018-0332088 LOTION (MOMETASONE) VS. VEHICLE IN PSORIASIS OF SCALP” | |
| “SCHER.ING STUDY C85-077-0132088 OINTMENT (MOMETASONE) VS. OINTMENT IN PSORlASIS; HPA. AXIS STUDIES” |
|
| “SCHERJNG STUDY C84-048-0532088 OINTMENT (MOMETASONE) VS. VALISONE OINTMENT IN ATOPIC DERMATITIS.” | |
| “HOECHST-ROUSSEL STUDY 303HOE 777 OINTMENT VS ARlSTOCORT A OINTMENT IN PSORJASIS” | |
| “HOECSHT-ROUSSEL STUDY 301HOE 777 OINTMENT VS VEHICLE IN PSORIASIS” | |
| “SCHER.ING STUDY C84-075-0232088 CREAM (MOMETASONE) VS. VEHICLE IN PSORIASIS” | |
| “SCHER.ING STUDY C85-028-0l EVALUATION OF CONTACT SENSITIZING POTENTIAL OF ALBUTEROL (PROVENTIL) IN TRANSDERMAL DELIVERY SYSTEM” | |
| “SCHERJNG STUDY P92-003-04 DIPROLENE VS TEMOVATE LOTION IN PSORJASIS OF SCALP” | |
| “HOECHST-ROUSSEL CICLOPIROZ GEL IN TINEA CRURIS” | |
| “SCHERING MOMETASONE FUROATE, 0.1% SALICYLIC ACID, 57 VS MOMETASONE FUROATE” |
Contact Us Today
Contact the Dermatology Group of Arkansas today. Call 501-227-8422.
